



DBV Technologies' first quarter 2013 Topline and cash position

Bagneux, France, April 15, 2013 - DBV Technologies (Euronext: DBV – ISIN: FR0010417345), creator of Viaskin[®], a new standard in the treatment of allergy, announced today its first quarter 2013 topline and cash position.

For the first three months 2013, total revenues reached €796,101, up from €735,124 a year earlier, driven by an increase in Research tax credit. This 11.2% increase stems from an intense R&D activity. DBV did not sell any batch of Diallertest[®] to its commercial partner over the period. In-market sales of Diallertest[®] reached 6598 units in France in the first three months 2013, reflecting a stable demand quarter-on-quarter.

As of March 31, 2013, DBV's cash position amounted to €34.7 million, compared with €37.8 million three months earlier.

DBV Technologies' shareholders' meeting will take place on June 4th at DBV' headquarter in Bagneux, 80/84 rue des Meuniers at 9:00 am.

About peanut allergy: a life-threatening risk for millions of people

In the US, about 1.1% of the general population, or over 3 million people, is allergic to peanuts, which results in about 100 to 150 deaths per year. This allergy affects both adults and children, and in the United Kingdom, it has been estimated that peanut allergy affects 1.8% of young children. The prevalence of peanut allergy in other Western countries (e.g., Canada, France and Spain) has been studied by many researchers, and the prevalence ranges from 0.9% to 1.5%. Peanut allergy is generally considered to be persistent; many studies indicate that fewer than 20% of children will outgrow their allergy. Peanut allergy is more severe than other common food allergies, including milk and egg allergies.

About DBV Technologies:

DBV Technologies is developing Viaskin[®], an innovative new approach to the treatment of allergies – a major public health issue that is constantly increasing in prevalence. Food allergies represent a true handicap in everyday life for millions of people, constituting a major unmet medical need. DBV Technologies, incorporated in France in 2002, has developed a proprietary, worldwide-patented technology for administering an allergen to intact skin while avoiding transfer to the blood. The Viaskin[®] technology combines efficacy and safety as part of a treatment that seeks to improve the patient's tolerability of peanuts, and thus considerably lowers the risk of a systemic, allergic reaction in the event of accidental exposure. The product's clinically proven safety profile enables the application of effective desensitization techniques in the most severe forms of the allergy. DBV Technologies is focusing on food allergies, including milk and peanut, for which there are currently no effective treatments. DBV Technologies has designed two products: Viaskin[®] Peanut and Viaskin[®] Milk. The clinical development program for Viaskin[®] Peanut has received Fast Track designation from the US Food and Drug Administration and is currently being studied in Phase II program. The company will subsequently develop a Viaskin[®] patch for young children with house dust mite allergy – a true public health issue because this pathology is a primary risk factor for childhood asthma.

DBV Technologies shares are traded on segment C of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345).

For more information on DBV Technologies, please visit our website: www.dbv-technologies.com



Contacts

DBV Technologies

David Schilansky
Chief Financial Officer
Tél. : +33(0)1 55 42 78 75

david.schilansky@dbv-technologies.com

US & UK investors

The Trout Group
Investor Relations
Alan S. Roemer
Tél. : +1 (212) 531-3315

aroemer@troutgroup.com

French investors

NewCap.
Financial Communication and investor relations
Emmanuel Huynh / Valentine Brouchet

Tél. : +33(0)1 44 71 94 94

dbv@newcap.fr

US press & media

Ronald Trahan, APR

Press relations

Ronald Trahan

Tél. : +1 508 359 4005

rctrahan@ronaldtrahan.com